|
1.
|
Burgess DJ: Histone modification at the
gene level. Nat Rev Cancer. 12:1562012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ganesan A, Nolan L, Crabb SJ and Packham
G: Epigenetic therapy: histone acetylation, DNA methylation and
anti-cancer drug discovery. Curr Cancer Drug Targets. 9:963–981.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lu Z, Luo RZ, Peng H, Huang M, Nishmoto A,
Hunt KK, Helin K, Liao WS and Yu Y: E2F-HDAC complexes negatively
regulate the tumor suppressor gene ARHI in breast cancer. Oncogene.
25:230–239. 2006.PubMed/NCBI
|
|
4.
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lehmann A, Denkert C, Budczies J,
Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M,
Neuhaus P, Dietel M, et al: High class I HDAC activity and
expression are associated with RelA/p65 activation in pancreatic
cancer in vitro and in vivo. BMC Cancer. 9:3952009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Wang L, Zou X, Berger AD, Twiss C, Peng Y,
Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al: Increased
expression of histone deacetylaces (HDACs) and inhibition of
prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J
Transl Res. 1:62–71. 2009.PubMed/NCBI
|
|
7.
|
Vanhaecke T, Papeleu P, Elaut G and
Rogiers V: Trichostatin A-like hydroxamate histone deacetylase
inhibitors as therapeutic agents: toxicological point of view. Curr
Med Chem. 11:1629–1643. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Marks PA: Discovery and development of
SAHA as an anticancer agent. Oncogene. 26:1351–1356. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lane AA and Chabner BA: Histone
deacetylase inhibitors in cancer therapy. J Clin Oncol.
27:5459–5468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Campas-Moya C: Romidepsin for the
treatment of cutaneous T-cell lymphoma. Drugs Today. 45:787–795.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Pettazzoni P, Pizzimenti S, Toaldo C,
Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L,
Atadja P, et al: Induction of cell cycle arrest and DNA damage by
the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation
end product 4-hydroxynonenal in prostate cancer cells. Free Radic
Biol Med. 50:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Phillip CJ, Giardina CK, Bilir B, Cutler
DJ, Lai YH, Kucuk O and Moreno CS: Genistein cooperates with the
histone deacetylase inhibitor vorinostat to induce cell death in
prostate cancer cells. BMC Cancer. 12:1452012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sweet MJ, Shakespear MR, Kamal NA and
Fairlie DP: HDAC inhibitors: modulating leukocyte differentiation,
survival, proliferation and inflammation. Immunol Cell Biol.
90:14–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Duenas-Gonzalez A, Lizano M, Candelaria M,
Cetina L, Arce C and Cervera E: Epigenetics of cervical cancer. An
overview and therapeutic perspectives. Mol Cancer. 4:382005.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Anton M, Horky M, Kuchtickova S, Vojtesek
B and Blaha O: Immunohistochemical detection of acetylation and
phosphorylation of histone H3 in cervical smears. Ceska Gynekol.
69:3–6. 2004.PubMed/NCBI
|
|
17.
|
Huang BH, Laban M, Leung CH, Lee L, Lee
CK, Salto-Tellez M, Raju GC and Hooi SC: Inhibition of histone
deacetylase 2 increases apoptosis and p21Cip1/WAF1
expression, independent of histone deacetylase 1. Cell Death
Differ. 12:395–404. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Vigushin DM, Ali S, Pace PE, Mirsaidi N,
Ito K, Adcock I and Coombes RC: Trichostatin A is a histone
deacetylase inhibitor with potent antitumor activity against breast
cancer in vivo. Clin Cancer Res. 7:971–976. 2001.PubMed/NCBI
|
|
19.
|
Zhang CZ, Zhang HT, Chen GG and Lai PB:
Trichostatin A sensitizes HBx-expressing liver cancer cells to
etoposide treatment. Apoptosis. 16:683–695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Meng J, Zhang HH, Zhou CX, Li C, Zhang F
and Mei QB: The histone deacetylase inhibitor trichostatin A
induces cell cycle arrest and apoptosis in colorectal cancer cells
via p53-dependent and -independent pathways. Oncol Rep. 28:384–388.
2012.PubMed/NCBI
|
|
21.
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Duan H, Heckman CA and Boxer LM: Histone
deacetylase inhibitors down-regulate bcl-2 expression and induce
apoptosis in t(14;18) lymphomas. Mol Cell Biol. 25:1608–1619. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ellis L and Pili R: Histone deacetylase
inhibitors: advancing therapeutic strategies in hematological and
solid malignancies. Pharmaceuticals. 3:2411–2469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Eot-Houllier G, Fulcrand G,
Magnaghi-Jaulin L and Jaulin C: Histone deacetylase inhibitors and
genomic instability. Cancer Lett. 274:169–176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ungerstedt JS, Sowa Y, Xu WS, Shao Y,
Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA:
Role of thioredoxin in the response of normal and transformed cells
to histone deacetylase inhibitors. Proc Natl Acad Sci USA.
102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Miriyala S, Spasojevic I, Tovmasyan A,
Salvemini D, Vujaskovic Z, St Clair D and Batinic-Haberle I:
Manganese superoxide dismutase, MnSOD and its mimics. Biochim
Biophys Acta. 1822:794–814. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hitchler MJ, Wikainapakul K, Yu L, Powers
K, Attatippaholkun W and Domann FE: Epigenetic regulation of
manganese superoxide dismutase expression in human breast cancer
cells. Epigenetics. 1:163–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Brechbuhl HM, Kachadourian R, Min E, Chan
D and Day BJ: Chrysin enhances doxorubicin-induced cytotoxicity in
human lung epithelial cancer cell lines: the role of glutathione.
Toxicol Appl Pharmacol. 258:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Fath MA, Ahmad IM, Smith CJ, Spence J and
Spitz DR: Enhancement of carboplatin-mediated lung cancer cell
killing by simultaneous disruption of glutathione and thioredoxin
metabolism. Clin Cancer Res. 17:6206–6217. 2011. View Article : Google Scholar : PubMed/NCBI
|
